Literature DB >> 7572077

Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: differentiation from progressive supranuclear palsy.

M B Feany1, H Ksiezak-Reding, W K Liu, I Vincent, S H Yen, D W Dickson.   

Abstract

Corticobasal degeneration (CBD) is a rare, progressive neurological disorder characterized by widespread neuronal and glial accumulation of abnormal tau protein. Using immunohistochemistry we analyzed tau epitope expression and phosphorylation state in CBD and compared them to cytoskeletal changes in Alzheimer's disease (AD) and progressive supranuclear palsy (PSP). Epitopes spanning the entire length of the tau protein were present in CBD inclusions. An antibody against the alternatively spliced exon 3 did not recognize cytoskeletal lesions in CBD, but did in AD and PSP. Tau epitopes from each region of the molecule were present in cytoskeletal inclusions in CBD, including gray matter astrocytic plaques, gray and white matter threads, and oligodendroglial inclusions. As in AD, tau from CBD was highly phosphorylated. Antibodies that recognized phosphorylated tau epitopes reacted with material from CBD in a highly phosphatase-dependent manner. Again, all types of inclusions contained phosphorylated epitopes. We conclude that abnormal tau protein in CBD comprises the entire tau molecule and is highly phosphorylated, but is distinguished from AD and PSP by the paucity of epitopes contained in the alternatively spliced exon 3.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572077     DOI: 10.1007/BF00294457

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  35 in total

Review 1.  Corticonigral degeneration with neuronal achromasia and basal neurofibrillary tangles.

Authors:  W Paulus; M Selim
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles.

Authors:  C Bancher; H Lassmann; H Budka; I Grundke-Iqbal; K Iqbal; G Wiche; F Seitelberger; H M Wisniewski
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

3.  Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome.

Authors:  I Tellez-Nagel; H M Wiśniewski
Journal:  Arch Neurol       Date:  1973-11

4.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

5.  Monoclonal antibodies to Alzheimer neurofibrillary tangles. 1. Identification of polypeptides.

Authors:  S H Yen; A Crowe; D W Dickson
Journal:  Am J Pathol       Date:  1985-08       Impact factor: 4.307

6.  Corticodentatonigral degeneration with neuronal achromasia.

Authors:  J J Rebeiz; E H Kolodny; E P Richardson
Journal:  Arch Neurol       Date:  1968-01

7.  Corticobasal degeneration: a disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy.

Authors:  H Mori; M Nishimura; Y Namba; M Oda
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

8.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

9.  Abnormal Tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type.

Authors:  S Flament; A Delacourte; M Verny; J J Hauw; F Javoy-Agid
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

10.  Tau protein function in living cells.

Authors:  D G Drubin; M W Kirschner
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more
  17 in total

1.  Tau isoform composition influences rate and extent of filament formation.

Authors:  Qi Zhong; Erin E Congdon; Haikady N Nagaraja; Jeff Kuret
Journal:  J Biol Chem       Date:  2012-04-26       Impact factor: 5.157

Review 2.  Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies.

Authors:  Yoshinari Miyata; John Koren; Janine Kiray; Chad A Dickey; Jason E Gestwicki
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

Review 3.  The new neuropathology of degenerative frontotemporal dementias.

Authors:  M Jackson; J Lowe
Journal:  Acta Neuropathol       Date:  1996       Impact factor: 17.088

4.  Familial multiple system tauopathy with presenile dementia: a disease with abundant neuronal and glial tau filaments.

Authors:  M G Spillantini; M Goedert; R A Crowther; J R Murrell; M R Farlow; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

Review 5.  Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies.

Authors:  Giulio Maria Pasinetti; Hanna Ksiezak-Reding; Ismael Santa-Maria; Jun Wang; Lap Ho
Journal:  J Neurochem       Date:  2010-07-27       Impact factor: 5.372

Review 6.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.

Authors:  D W Dickson
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

7.  Ultrastructural instability of paired helical filaments from corticobasal degeneration as examined by scanning transmission electron microscopy.

Authors:  H Ksiezak-Reding; E Tracz; L S Yang; D W Dickson; M Simon; J S Wall
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

8.  Expression of the small heat-shock protein alphaB-crystallin in tauopathies with glial pathology.

Authors:  Deepa V Dabir; John Q Trojanowski; Christiane Richter-Landsberg; Virginia M-Y Lee; Mark S Forman
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

9.  Haplotype-specific expression of the N-terminal exons 2 and 3 at the human MAPT locus.

Authors:  Tara M Caffrey; Catharine Joachim; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-28       Impact factor: 4.673

Review 10.  Chaperone signalling complexes in Alzheimer's disease.

Authors:  John Koren; Umesh K Jinwal; Daniel C Lee; Jeffrey R Jones; Cody L Shults; Amelia G Johnson; Laura J Anderson; Chad A Dickey
Journal:  J Cell Mol Med       Date:  2009-04       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.